Which has stronger earnings and valuation, QGEN or MRVI?

Qiagen has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.09B 4.25 $424.88M $1.95 22.09 Maravai LifeSciences $185.74M 10.74 -$130.77M -$0.52 N/A

Does the media favor QGEN or MRVI?

In the previous week, Qiagen had 16 more articles in the media than Maravai LifeSciences. MarketBeat recorded 22 mentions for Qiagen and 6 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.45 beat Qiagen's score of 0.26 indicating that Maravai LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maravai LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BRKR or MRVI?

In the previous week, Bruker had 4 more articles in the media than Maravai LifeSciences. MarketBeat recorded 10 mentions for Bruker and 6 mentions for Maravai LifeSciences. Bruker's average media sentiment score of 1.77 beat Maravai LifeSciences' score of 0.45 indicating that Bruker is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bruker 9 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Maravai LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TXG or MRVI?

In the previous week, 10x Genomics had 10 more articles in the media than Maravai LifeSciences. MarketBeat recorded 16 mentions for 10x Genomics and 6 mentions for Maravai LifeSciences. 10x Genomics' average media sentiment score of 0.47 beat Maravai LifeSciences' score of 0.45 indicating that 10x Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maravai LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MRVI or CAI?

In the previous week, Caris Life Sciences had 2 more articles in the media than Maravai LifeSciences. MarketBeat recorded 8 mentions for Caris Life Sciences and 6 mentions for Maravai LifeSciences. Caris Life Sciences' average media sentiment score of 1.17 beat Maravai LifeSciences' score of 0.45 indicating that Caris Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Caris Life Sciences 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer STVN or MRVI?

Maravai LifeSciences has a consensus target price of $6.25, indicating a potential downside of 18.62%. Given Maravai LifeSciences' higher possible upside, analysts clearly believe Maravai LifeSciences is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00 Maravai LifeSciences 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor STVN or MRVI?

In the previous week, Maravai LifeSciences had 3 more articles in the media than Stevanato Group. MarketBeat recorded 6 mentions for Maravai LifeSciences and 3 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 1.12 beat Maravai LifeSciences' score of 0.45 indicating that Stevanato Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stevanato Group 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maravai LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Maravai LifeSciences (MRVI) Competitors

$7.68 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$7.70 +0.03 (+0.33%)

As of 07:07 AM Eastern

Compare

MRVI vs. QGEN, BRKR, TXG, CAI, and STVN

Should you buy Maravai LifeSciences stock or one of its competitors? Maravai LifeSciences's main competitors and comparable companies include Qiagen (QGEN), Bruker (BRKR), 10x Genomics (TXG), Caris Life Sciences (CAI), and Stevanato Group (STVN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Maravai LifeSciences compare to Qiagen?

Qiagen (NYSE:QGEN) and Maravai LifeSciences (NASDAQ:MRVI) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

Qiagen has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	4.25	$424.88M	$1.95	22.09
Maravai LifeSciences	$185.74M	10.74	-$130.77M	-$0.52	N/A

In the previous week, Qiagen had 16 more articles in the media than Maravai LifeSciences. MarketBeat recorded 22 mentions for Qiagen and 6 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.45 beat Qiagen's score of 0.26 indicating that Maravai LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maravai LifeSciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

70.0% of Qiagen shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Qiagen has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

Qiagen has a net margin of 19.49% compared to Maravai LifeSciences' net margin of -37.07%. Qiagen's return on equity of 14.47% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.49%	14.47%	8.34%
Maravai LifeSciences	-37.07%	-15.70%	-8.17%

Qiagen currently has a consensus target price of $43.93, suggesting a potential upside of 1.96%. Maravai LifeSciences has a consensus target price of $6.25, suggesting a potential downside of 18.62%. Given Qiagen's stronger consensus rating and higher possible upside, research analysts clearly believe Qiagen is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.43
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Qiagen beats Maravai LifeSciences on 14 of the 16 factors compared between the two stocks.

How does Maravai LifeSciences compare to Bruker?

Bruker (NASDAQ:BRKR) and Maravai LifeSciences (NASDAQ:MRVI) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

Bruker currently has a consensus price target of $56.64, indicating a potential downside of 0.77%. Maravai LifeSciences has a consensus price target of $6.25, indicating a potential downside of 18.62%. Given Bruker's stronger consensus rating and higher possible upside, research analysts clearly believe Bruker is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bruker	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.57
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Bruker has a net margin of -2.35% compared to Maravai LifeSciences' net margin of -37.07%. Bruker's return on equity of 12.47% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bruker	-2.35%	12.47%	4.91%
Maravai LifeSciences	-37.07%	-15.70%	-8.17%

Bruker has higher revenue and earnings than Maravai LifeSciences. Bruker is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bruker	$3.44B	2.53	-$8.60M	-$0.70	N/A
Maravai LifeSciences	$185.74M	10.74	-$130.77M	-$0.52	N/A

Bruker has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

79.5% of Bruker shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 27.2% of Bruker shares are owned by insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Bruker had 4 more articles in the media than Maravai LifeSciences. MarketBeat recorded 10 mentions for Bruker and 6 mentions for Maravai LifeSciences. Bruker's average media sentiment score of 1.77 beat Maravai LifeSciences' score of 0.45 indicating that Bruker is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bruker	9 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Maravai LifeSciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Bruker beats Maravai LifeSciences on 14 of the 17 factors compared between the two stocks.

How does Maravai LifeSciences compare to 10x Genomics?

10x Genomics (NASDAQ:TXG) and Maravai LifeSciences (NASDAQ:MRVI) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

10x Genomics presently has a consensus target price of $38.31, indicating a potential downside of 37.75%. Maravai LifeSciences has a consensus target price of $6.25, indicating a potential downside of 18.62%. Given Maravai LifeSciences' higher probable upside, analysts plainly believe Maravai LifeSciences is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.25
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

10x Genomics has a beta of 2.03, indicating that its stock price is 103% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market.

84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, 10x Genomics had 10 more articles in the media than Maravai LifeSciences. MarketBeat recorded 16 mentions for 10x Genomics and 6 mentions for Maravai LifeSciences. 10x Genomics' average media sentiment score of 0.47 beat Maravai LifeSciences' score of 0.45 indicating that 10x Genomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maravai LifeSciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

10x Genomics has a net margin of -12.18% compared to Maravai LifeSciences' net margin of -37.07%. 10x Genomics' return on equity of -9.33% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-12.18%	-9.33%	-7.30%
Maravai LifeSciences	-37.07%	-15.70%	-8.17%

10x Genomics has higher revenue and earnings than Maravai LifeSciences. 10x Genomics is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	12.47	-$43.54M	-$0.59	N/A
Maravai LifeSciences	$185.74M	10.74	-$130.77M	-$0.52	N/A

Summary

10x Genomics beats Maravai LifeSciences on 13 of the 16 factors compared between the two stocks.

How does Maravai LifeSciences compare to Caris Life Sciences?

Maravai LifeSciences (NASDAQ:MRVI) and Caris Life Sciences (NASDAQ:CAI) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

In the previous week, Caris Life Sciences had 2 more articles in the media than Maravai LifeSciences. MarketBeat recorded 8 mentions for Caris Life Sciences and 6 mentions for Maravai LifeSciences. Caris Life Sciences' average media sentiment score of 1.17 beat Maravai LifeSciences' score of 0.45 indicating that Caris Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Caris Life Sciences	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

50.3% of Maravai LifeSciences shares are held by institutional investors. 2.5% of Maravai LifeSciences shares are held by insiders. Comparatively, 50.0% of Caris Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Maravai LifeSciences has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market. Comparatively, Caris Life Sciences has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

Maravai LifeSciences presently has a consensus price target of $6.25, indicating a potential downside of 18.62%. Caris Life Sciences has a consensus price target of $26.33, indicating a potential upside of 2.74%. Given Caris Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Caris Life Sciences is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Caris Life Sciences has a net margin of 10.62% compared to Maravai LifeSciences' net margin of -37.07%. Caris Life Sciences' return on equity of 18.77% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.70%	-8.17%
Caris Life Sciences	10.62%	18.77%	9.34%

Caris Life Sciences has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	10.74	-$130.77M	-$0.52	N/A
Caris Life Sciences	$812.03M	8.92	-$68.09M	$0.36	71.19

Summary

Caris Life Sciences beats Maravai LifeSciences on 14 of the 16 factors compared between the two stocks.

How does Maravai LifeSciences compare to Stevanato Group?

Stevanato Group (NYSE:STVN) and Maravai LifeSciences (NASDAQ:MRVI) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

50.3% of Maravai LifeSciences shares are held by institutional investors. 0.7% of Stevanato Group shares are held by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Maravai LifeSciences had 3 more articles in the media than Stevanato Group. MarketBeat recorded 6 mentions for Maravai LifeSciences and 3 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 1.12 beat Maravai LifeSciences' score of 0.45 indicating that Stevanato Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stevanato Group	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maravai LifeSciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Maravai LifeSciences has a consensus target price of $6.25, indicating a potential downside of 18.62%. Given Maravai LifeSciences' higher possible upside, analysts clearly believe Maravai LifeSciences is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Stevanato Group has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market.

Stevanato Group has a net margin of 10.99% compared to Maravai LifeSciences' net margin of -37.07%. Stevanato Group's return on equity of 10.43% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	10.99%	10.43%	6.16%
Maravai LifeSciences	-37.07%	-15.70%	-8.17%

Stevanato Group has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	€1.23B	5.22	€158.21M	€0.56	37.68
Maravai LifeSciences	$185.74M	10.74	-$130.77M	-$0.52	N/A

Summary

Stevanato Group beats Maravai LifeSciences on 11 of the 16 factors compared between the two stocks.

Get Maravai LifeSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRVI vs. The Competition

Export

Metric	Maravai LifeSciences	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.99B	$9.98B	$7.18B	$12.88B
Dividend Yield	N/A	1.46%	2.54%	11.27%
P/E Ratio	-14.77	62.76	273.17	25.45
Price / Sales	10.74	111.59	637.96	103.59
Price / Cash	18.35	26.70	28.74	36.03
Price / Book	5.26	5.49	11.08	6.36
Net Income	-$130.77M	$56.67B	$3.48B	$349.79M
7 Day Performance	-8.90%	-0.82%	0.21%	-0.48%
1 Month Performance	16.89%	8.71%	7.75%	4.17%
1 Year Performance	217.36%	24.31%	24.68%	15.11%

Maravai LifeSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRVI Maravai LifeSciences	1.3146 of 5 stars	$7.68 flat	$6.25 -18.6%	+217.4%	$1.99B	$185.74M	N/A	610	Analyst Downgrade Gap Up
QGEN Qiagen	2.7532 of 5 stars	$42.82 +2.5%	$43.93 +2.6%	-12.1%	$8.83B	$2.09B	21.95	5,654	Trending News
BRKR Bruker	2.9387 of 5 stars	$57.32 +0.6%	$56.64 -1.2%	+68.0%	$8.74B	$3.44B	N/A	11,085	Positive News
TXG 10x Genomics	1.4976 of 5 stars	$65.96 +3.4%	$38.31 -41.9%	+339.3%	$8.60B	$642.82M	N/A	1,240	Insider Trade Gap Up
CAI Caris Life Sciences	2.4334 of 5 stars	$27.32 +4.6%	$26.33 -3.6%	N/A	$7.68B	$812.03M	75.49	1,846	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRVI) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maravai LifeSciences (MRVI) Competitors

MRVI vs. QGEN, BRKR, TXG, CAI, and STVN

How does Maravai LifeSciences compare to Qiagen?

Summary

How does Maravai LifeSciences compare to Bruker?

Summary

How does Maravai LifeSciences compare to 10x Genomics?

Summary

How does Maravai LifeSciences compare to Caris Life Sciences?

Summary

How does Maravai LifeSciences compare to Stevanato Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRVI vs. The Competition

Maravai LifeSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maravai LifeSciences (MRVI) Competitors

MRVI vs. QGEN, BRKR, TXG, CAI, and STVN

How does Maravai LifeSciences compare to Qiagen?

Which has stronger earnings and valuation, QGEN or MRVI?

Does the media favor QGEN or MRVI?

Do institutionals and insiders have more ownership in QGEN or MRVI?

Which has more risk & volatility, QGEN or MRVI?

Is QGEN or MRVI more profitable?

Do analysts recommend QGEN or MRVI?

Summary

How does Maravai LifeSciences compare to Bruker?

Do analysts rate BRKR or MRVI?

Is BRKR or MRVI more profitable?

Which has better valuation & earnings, BRKR or MRVI?

Which has more volatility and risk, BRKR or MRVI?

Do institutionals & insiders have more ownership in BRKR or MRVI?

Does the media favor BRKR or MRVI?

Summary

How does Maravai LifeSciences compare to 10x Genomics?

Do analysts rate TXG or MRVI?

Which has more volatility & risk, TXG or MRVI?

Do insiders & institutionals have more ownership in TXG or MRVI?

Does the media favor TXG or MRVI?

Is TXG or MRVI more profitable?

Which has higher earnings and valuation, TXG or MRVI?

Summary

How does Maravai LifeSciences compare to Caris Life Sciences?

Does the media prefer MRVI or CAI?

Do insiders and institutionals believe in MRVI or CAI?

Which has more risk and volatility, MRVI or CAI?

Do analysts rate MRVI or CAI?

Is MRVI or CAI more profitable?

Which has better earnings and valuation, MRVI or CAI?

Summary

How does Maravai LifeSciences compare to Stevanato Group?

Do insiders & institutionals have more ownership in STVN or MRVI?

Does the media favor STVN or MRVI?

Do analysts prefer STVN or MRVI?

Which has more risk and volatility, STVN or MRVI?

Is STVN or MRVI more profitable?

Which has preferable earnings and valuation, STVN or MRVI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRVI vs. The Competition

Maravai LifeSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools